Coronavirus Vaccine

Munira Wilson Excerpts

Wednesday 2nd December 2020 Commons Chamber

[Matt Hancock]

My right hon. Friend is gracious and kind in what he says, and I welcome the WHO’s comments this morning. It has supported the UK approach and rightly commended the MHRA, our independent regulator. It has followed all the same steps that any high-quality regulator would, should and will, but it has followed them rapidly and sometimes in parallel, instead of one after the other. That is how we have got to the position of being the first country in the world to have a vaccine that is clinically authorised; it is because the MHRA has done a brilliant job, working with Pfizer and BioNTech, to make sure that the same safety considerations are looked at but in a way that made the process as fast as is feasibly and safely possible. The WHO has backed that approach. Regulators around the world could take a look at the MHRA, and we should all congratulate it.

My right hon. Friend rightly asks about making sure we vaccinate those with learning disabilities and offer them vaccination at the right point in the prioritisation. I have discussed that important consideration directly with the JCVI, which takes into account the higher mortality of those with any given condition and has done so in the prioritisation that it set out this morning. Age is the single biggest determinant of mortality from coronavirus, which is why age is the predominant factor in the prioritisation, but it is not the only one. That matter has been considered by the JCVI and it is important that we accept and follow the JCVI advice as much as is practicable in the delivery and deployment of this vaccine.

[Munira Wilson (Twickenham) (LD)]

It is, indeed, a fantastic day. I add my thanks and congratulations to everybody who has been involved in getting us to this point, not just in the UK, but worldwide, because this is a great example of global scientific collaboration. May I also pick up on the point about batch testing, which the Secretary of State mentioned on the radio this morning and in his statement? Will he clarify that if we signed up to a mutual recognition agreement with the EU, we would not need to batch test the vaccine again once it arrives in the UK, which could slow down the process, not least because having enough qualified persons to do the batch release testing could be a real challenge? Is he working on a mutual recognition agreement?

[Matt Hancock]

We have that mutual recognition agreement in place now. The hon. Lady is right to point to the global scientific work—work between UK scientists and scientists based in the UK, German scientists at BioNTech, the American scientists and the Belgians, who are producing and manufacturing this vaccine. The approach has been about people coming together right around the world, and the UK has put more into the global search for a vaccine in cash terms than any other country; despite our medium size as a nation, we have been the most generous, and I am really proud of that.